日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

pH-dependent dissociation from CTLA-4 in early endosomes improves both safety and antitumor activity of anti-CTLA-4 antibodies

早期内体中pH依赖性地从CTLA-4解离可提高抗CTLA-4抗体的安全性和抗肿瘤活性。

Zhang, Meiyu; Li, Jinmei; Yan, Kepeng; Zhou, Haoyue; Mei, Song; Wang, Benyu; Li, Dongyang; Du, Xuexiang; Liu, Mingyue; Zhang, Peng; Fields, James K; Ye, Lei; Zheng, Pan; Liu, Yang; Lenardo, Michael J; Zhang, Yan

CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect

CD24Fc 可减轻免疫相关不良反应,同时保持抗肿瘤治疗效果。

Liu, Mingyue; Wang, Xu; Du, Xuexiang; Zhang, Yan; Ai, Chunxia; Hu-Lieskovan, Siwen; Li, Tianhong; Devenport, Martin; Liu, Yang; Zheng, Pan

Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies.

基于机制和免疫图谱对 22 种主要人类癌症对下一代抗 CTLA-4 抗体的治疗反应进行排序

Zhang Peng, Xiong Xinxin, Rolfo Christian, Du Xuexiang, Zhang Yan, Yang Han, Russo Alessandro, Devenport Martin, Zhou Penghui, Liu Yang, Zheng Pan

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?

抗CTLA-4抗体在癌症免疫疗法中的应用:选择性清除肿瘤内调节性T细胞还是阻断免疫检查点?

Tang, Fei; Du, Xuexiang; Liu, Mingyue; Zheng, Pan; Liu, Yang

Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses

高IL-15通过促进肿瘤特异性CD8+ T细胞反应来抑制转移性和原发性肝癌。

Cheng, Liang; Du, Xuexiang; Wang, Zheng; Ju, Jianqi; Jia, Mingming; Huang, Qibin; Xing, Qiao; Xu, Meng; Tan, Yi; Liu, Mingyue; Du, Peishuang; Su, Lishan; Wang, Shengdian

Immunotherapy of metastatic and autochthonous liver cancer with IL-15/IL-15Rα fusion protein

利用IL-15/IL-15Rα融合蛋白进行转移性和原发性肝癌的免疫治疗

Cheng, Liang; Du, Xuexiang; Su, Lishan; Wang, Shengdian

The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody

肿瘤免疫抑制微环境会削弱抗HER2/neu抗体的治疗效果。

Xu, Meng; Du, Xuexiang; Liu, Mingyue; Li, Sirui; Li, Xiaozhu; Fu, Yang-Xin; Wang, Shengdian